Prescription of anti-inflammatory drugs may be considered as a promising strategy in chronic wound healing where the inflammatory disturbance has delayed the healing process. It seems that hydrocortisone 17-butyrate (HB17) would be promising in the form of a nano-formulation to enhance drug delivery efficacy. In the present study, transdermal delivery of nano-HB17 in combination with iontophoresis was investigated ex vivo. Ethosomal-HB17 was synthesised using lecithin, ethanol and cholesterol with a different ratio by hot method. The negative ethosomal-HB17 particle size was around 244 ± 4.3 nm with high stability of up to 30 days. Additionally, evaluated entrapment efficiency of HB17 in ethosomes by high performance liquid chromatography was 40.6 ± 2.21%. Moreover, the permeation speed and amount of H17B in complete-thickness rat skin in the presence and absence of iontophoresis showed that the penetration of free H17B and ethosomal-H17B formulations were zero and 7.98 μg/cm2 in 120 min, respectively. Whereas in the case of applying iontophoresis, permeation amount obtained was zero and 19.69 μg/cm2 in 30 min in free H17B and ethosomal-H17B formulations, respectively. It has been concluded that transdermal delivery of ethosomal-H17B is an effective strategy to enhance drug delivery and it will be improved when it is combined with iontophoresis.
Keywords: chronic wound healing; ethosome; hydrocortisone 17-butyrate; nano-carrier; nanoparticle; transdermal delivery.
© 2021 The Authors. IET Nanobiotechnology published by John Wiley & Sons Ltd on behalf of The Institution of Engineering and Technology.